Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide timing study: main meal versus breakfast in type 2 diabetes on metformin
2011-002416-85Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c. Started Jan 2012; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002416-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002416-85.